Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ijd.15028 http://scihub22266oqcxt.onion/10.1111/ijd.15028 32621284!7361427!32621284     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Dermatol 2020 ; 59 (9): 1043-1056 Nephropedia Template TP {{tp|p=32621284|t=2020. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration |pdf=|usr=}}{{32621284}} gab.com Text Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration JO: Int J Dermatol http://www.kidney.de/pget.php?&tw=1&pmid=32621284 #FOAvip Recommendations were made recently to limit or stop the use of oral and systemic immunotherapies for skin diseases due to potential risks to the patients during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic. Herein, we attempt to identify potentially safe immunotherapies that may be used in the treatment of cutaneous diseases during the current COVID-19 pandemic. We performed a literature review to approximate the risk of SARS-CoV-2 infection, including available data on the roles of relevant cytokines, cell subsets, and their mediators in eliciting an optimal immune response against respiratory viruses in murine gene deletion models and humans with congenital deficiencies were reviewed for viral infections risk and if possible coronaviruses specifically. Furthermore, reported risk of infections of biologic and non-biologic therapeutics for skin diseases from clinical trials and drug data registries were evaluated. Many of the immunotherapies used in dermatology have data to support their safe use during the COVID-19 pandemic including the biologics that target IgE, IL-4/13, TNF-alpha, IL-17, IL-12, and IL-23. Furthermore, we provide evidence to show that oral immunosuppressive medications such as methotrexate and cyclosporine do not significantly increase the risk to patients. Most biologic and conventional immunotherapies, based on doses and indications in dermatology, do not appear to increase risk of viral susceptibility and are most likely safe for use during the COVID-19 pandemic. The limitation of this study is availability of data on COVID-19. Twit Text FOAVip Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration ????Int J Dermatol http://www.kidney.de/pget.php?&tw=1&pmid=32621284 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32621284 #FOAvip English Wikipedia <ref>{{Cite pmid|32621284}}</ref> Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration #MMPMID32621284 Ghazawi FM; Lim M; Dutz JP; Kirchhof MG Int J Dermatol 2020[Sep]; 59 (9): 1043-1056 PMID32621284show ga Recommendations were made recently to limit or stop the use of oral and systemic immunotherapies for skin diseases due to potential risks to the patients during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic. Herein, we attempt to identify potentially safe immunotherapies that may be used in the treatment of cutaneous diseases during the current COVID-19 pandemic. We performed a literature review to approximate the risk of SARS-CoV-2 infection, including available data on the roles of relevant cytokines, cell subsets, and their mediators in eliciting an optimal immune response against respiratory viruses in murine gene deletion models and humans with congenital deficiencies were reviewed for viral infections risk and if possible coronaviruses specifically. Furthermore, reported risk of infections of biologic and non-biologic therapeutics for skin diseases from clinical trials and drug data registries were evaluated. Many of the immunotherapies used in dermatology have data to support their safe use during the COVID-19 pandemic including the biologics that target IgE, IL-4/13, TNF-alpha, IL-17, IL-12, and IL-23. Furthermore, we provide evidence to show that oral immunosuppressive medications such as methotrexate and cyclosporine do not significantly increase the risk to patients. Most biologic and conventional immunotherapies, based on doses and indications in dermatology, do not appear to increase risk of viral susceptibility and are most likely safe for use during the COVID-19 pandemic. The limitation of this study is availability of data on COVID-19. |Animals[MESH] |Betacoronavirus/immunology[MESH] |Biological Products/adverse effects[MESH] |COVID-19[MESH] |Coronavirus Infections/complications/diagnosis/*epidemiology/immunology[MESH] |Cytokine Release Syndrome/*immunology/virology[MESH] |Dermatologic Agents/*adverse effects[MESH] |Dermatology/methods/statistics & numerical data[MESH] |Disease Models, Animal[MESH] |Disease Susceptibility/*chemically induced/immunology[MESH] |Evidence-Based Medicine/methods/statistics & numerical data[MESH] |Humans[MESH] |Immunologic Factors/adverse effects[MESH] |Mice[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/diagnosis/*epidemiology/immunology[MESH] |Randomized Controlled Trials as Topic[MESH] |Risk Assessment[MESH] |SARS-CoV-2[MESH] |Severity of Illness Index[MESH]Infection risk of dermatologic therapeutics during the COVID-19 pandem(epmc).pdf DeepDyve Pubget Overpricing